The first state opioid trial has begun in Oklahoma. Johnson & Johnson, the only remaining defendant in the case, and the state gave opening statements on Tuesday. The other two drugmakers named in the lawsuit settled before the trial began. (MM&M)

The number of new diabetes cases is falling, even as obesity rates rise. New diabetes diagnoses dropped to 1.3 million in 2017, down from 1.7 million in 2009, according to federal data. Officials haven’t pinpointed what’s driving the downward trend. (Associated Press)

Juul is struggling to recruit scientists. The company needs top-tier scientists to prove to the Food and Drug Administration that its e-cigarettes are safe, but many aren’t comfortable working for the company. (New York Times)

Amazon removed books promoting dangerous bleach “cures” for autism. The online retailer removed more than a dozen titles that claimed homemade bleach can cure autism and conditions like malaria. Companies such as Amazon are battling the spread of online health misinformation. (CNBC)

Allergan’s Vraylar has received FDA approval to treat bipolar depression. Vraylar has been okayed to treat schizophrenia in adults and for manic or mixed episodes associated with bipolar I disorder. With the label expansion, the drug is expected to bring in $1.3 billion in sales by 2026. (Reuters)